Is A Clozapine REMS Still Needed? Two US FDA Adcomms Will Weigh Neutropenia Risk Mitigation

The antipsychotic’s Risk Evaluation and Mitigation Strategy has never been fully implemented or enforced due to operational and technical challenges. The FDA now is re-evaluating the need for the program given changes in the health care landscape and medical training since the drug’s 1989 approval.